Vulvar intraepithelial neoplasia (VIN) is an increasingly common problem, particularly among women in their 40s. VIN should be considered a premalignant condition. Immunization with the quadrivalent or 9-valent human papillomavirus vaccine, which is effective against human papillomavirus genotypes has been shown to decrease the risk of vulvar high-grade squamous intraepithelial lesion and should be recommended for girls aged 11–12 years with catch-up through age 26 years if not vaccinated in the target age.
There are no screening strategies for the prevention of vulvar cancer through early detection of vulvar HSIL (VIN usual type). Treatment is recommended for all women with vulvar HSIL (VIN usual type). Given the relatively slow rate of progression, women with a complete response to therapy and no new lesions at follow-up visits scheduled 6 months and 12 months after initial treatment should be monitored by visual inspection of the vulva annually thereafter.
Most women with vulvar intraepithelial neoplasia (VIN) have no symptoms at all. When a woman with VIN does have a symptom, it is most often itching that does not go away or get better. An area of VIN may look different from normal vulvar skin. It is often thicker and lighter than the normal skin around it. However, an area of VIN can also appear red, pink, or darker than the surrounding skin. READ MORE